Amplia Therapeutics (ASX:ATX) has reported updated data from its ongoing Phase 2a ACCENT clinical trial investigating its FAK inhibitor narmafotinib in combination with standard-of-care chemotherapy in treating advanced pancreatic cancer.
Recruitment for the Phase 2a trial began in January 2024 and was completed ahead of schedule in January this year. A total of 55 advanced pancreatic patients have enrolled in the study at the trial sites in Australia and Korea. The trial is fully enrolled, and as of 12 March 2025, 29 patients remain in study.
The primary endpoint for the study is the objective response rate, where data for the narmafotinib and chemotherapy combination is compared against historical data for chemotherapy treatment alone.
Amplia said that at this time, 13 confirmed partial responses (PRs) have been observed, noting that tumour shrinkage assessments for most patients enrolled since December are yet to be undertaken. The company said an outcome of 15 PR’s or more, by the end of the study, would indicate the narmafotinib combination performs better than chemotherapy alone.
Amplia CEO and managing director Dr Chris Burns said, “Data from the ACCENT trial continues to be extremely positive, with promising efficacy and good tolerability observed to date, and with tumour responses still being measured for the patients remaining on study. Our scheduled presentation of additional data at AACR, one of the world’s premier cancer meetings, allows us to engage with clinicians and scientists about the considerable potential narmafotinib is demonstrating in the treatment of pancreatic cancer.”